The direct costs of multiple sclerosis—study in the Czech Republic
Multiple sclerosis (MS) is a progressive autoimmune disease of the central nervous system that is often disabling and for which there is currently no cure, though disease-modifying treatment is now available. The aim of this study is to describe the current values of the direct costs of multiple sclerosis (MS) in the Czech Republic.
Attention is focused on direct medical costs. The costs were monitored in the Czech Republic among 5673 patients in the period between 2011 and 2015. These costs included complex, special and targeted visits at the neurologist, blood collection and the costs of hospitalisation. The results refer to the diagnoses according to the International Statistical Classification of Diseases and Related Health Problems. The attention is focused on MS G35 (NS; brain stem; spinal cord; disseminated; generalised).
The average total direct costs per patient per year are 4838.1 €. Not every patient has to be hospitalised during the year, and not every patient has prescribed medication. According to the above data, 12% of patients are hospitalised and 55% of patients are prescribed medication. The minimum average cost per patient without medication and hospitalisation is 54.1 €.
Cost evaluation across countries is difficult due to the different evidence. If only selected direct costs considered in this study are compared, the absolute economics burden increases over time. The only statistically significant difference in the average price and the time spent is between 2012 and 2013, where the correlation value is 0.597.
KeywordsNeurological disease Multiple sclerosis Direct costs Czech Republic
JEL classificationI1 I15 J14
This study was supported by the TACR AD (University of Hradec Kralove, Faculty of Informatics and Management), by an internal project at the Faculty Informatics and Management, and by the Long-term development plan UHHK.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no competing interests.
Ethics approval and consent to participate
- 2.Havrdova E, Kobelt G, Berg J, Capsa D, Gannedahl M, Doležal T, The European Multiple Sclerosis Platform (2017) New insights into the burden and costs of multiple sclerosis in Europe: results of the Czech Republic. Mult Scler 23(2_suppl):41–52. https://doi.org/10.1177/1352458517708117 CrossRefPubMedGoogle Scholar
- 14.Barták M, Gavúrová B (2014) Economics and social aspects of long-term care in the context of the Czech Republic and the Slovak Republic EU membership. In: Proceedings of 12th International scientific conference: economic policy in the European Union member countries, PTS I and II, vol 2015. Ostravice, Czech Republic, pp 35–44Google Scholar
- 15.Dlouhý M, Barták M (2013) Mental health financing in six Eastern European countries 16(4):4–13Google Scholar
- 19.World Health Organization (2003) Guide to producing national accounts with special applications for low-income and middle-income countries. [online] Available from: http://www.who.int/health-accounts/documentation/publication_nha_guide/en/
- 20.Drummond MF, O’Brien BJ (1997) Methods for the economic evaluation of health care programs (Oxford Medical Publications), 2nd edn. Oxford Medical PublicationGoogle Scholar
- 21.Rascati KL (2014) Essentials of pharmacoeconomics, 2nd edn. Wolters Kluwer Health/Lippincott Williams, PhiladelphiaGoogle Scholar
- 22.IMPULS Endowment Fund (2016) Regular output from the ReMuS registry. Available at: http://www.multiplesclerosis.cz/docs/160914_remus_zaverecna-zprava_2016_06_souhrnna_14_9.pdf
- 23.Department of Neurology, University Hospital Hradec Králové (2014) Available from: http://www.fnhk.cz/neuro
- 24.General Health Insurance Company (Všeobecná zdravotní pojišťovna) (2015). Annual report 2013. [online] Available from: http://www.vzp.cz/uploads/document/vzp-rocenka-2013.pdf